Working alongside the executive teams of the portfolio companies, Dr Willcocks played an integral role in out-licensing transactions, co-development deals and acquisitions. Ultimately leading the Life Science team, Dr Willcocks' role encompassed all aspects of technology commercialisation, including spin-out company formation and business and corporate development, as well as private and public equity financings.ĭr Willcocks was a key player in the creation of 14 life science businesses based on technology from three universities, leading proposals for the investment of £4m in seed financing from IPGroup and holding positions of Director and Chairman for 6 portfolio companies. During this time, he was instrumental in the launch of several generations of blood glucose bio-electronic systems for the consumer and hospital medical markets.ĭr Spike Willcocks Chief Strategy OfficerĪfter completing an MA in Chemistry and a DPhil in Biochemistry at the University of Oxford, Dr Willcocks became one of the initial members of IPGroup Plc following its landmark deal with the Chemistry Department at Oxford. These platforms are used in more than 100 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments.ĭr Sanghera’s PhD in bioelectronic technology was followed by a career at MediSense - an Oxford spin-out that delivered a new generation glucose technology to the market - where he held positions including VP World Wide Marketing, Research Director and Manufacturing Process Development Director.
David production team size portable#
The company has been commercially distributing sequencing platforms since 2015, including the handheld and portable MinION and Flongle, and the high-throughput benchtop devices, GridION and PromethION.
The first products enable the real-time, high-performance, accessible and scalable analysis of DNA and RNA, and this new class of sensing has the potential to expand into proteomics and metabolomics.įully bespoke manufacturing capability has been built from the ground up, integrating state of the art electronics with silicon fab technology combining the chemistry and biology. He was appointed CEO in May 2005 and has led the company through multiple finance rounds, and in 2021, a listing on the London Stock Exchange. The company has developed a new generation of nanopore-based sensing technology. Gordon Sanghera is co-founder of Oxford Nanopore with Spike Willcocks and Hagan Bayley. Team members are encouraged to set their own research goals, allowing the Brain team to maintain a portfolio of projects across varied time horizons, research areas and levels of risk.Dr Gordon Sanghera Chief Executive Officer We believe that openly disseminating research is critical to a healthy exchange of ideas, leading to rapid progress in the field.Īs such, we regularly publish our research at top academic conferences and journals, and release our tools, such as TensorFlow and Jax, as open-source projects. Our broad and fundamental research goals allow us to collaborate with and contribute to many teams across Alphabet, which deploy our cutting-edge technology into products used by billions of users, positively impacting society and the research community. Google impactĪs part of Google and Alphabet, the Brain team has access to resources and unparalleled collaboration opportunities that have a positive impact on products and society. Our research breakthroughs enable Google’s mission to organize the world's information and make it universally accessible and useful.
0 kommentar(er)
